Zahav Biosciences and the Race to Accelerate Cancer Drug Development
In an industry defined by long timelines, high failure rates, and immense capital needs, Zahav Biosciences represents a new breed of oncology-focused biotechnology startup driven by speed and personal mission. The company, formed in 2023 from the rebranded assets of Cytimmune Sciences, has charted an ambitious course: compress drug development timelines, target lethal cancers with…
